Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

NCT02488967 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT02488967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02488967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Lead sponsor
NRG Oncology
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 26, 2015
Completion date
October 31, 2026
Enrollment
782 (estimated)
Sites
1,296

Conditions

As the registry lists them; a condition with its own page is linked.

breast adenocarcinoma, estrogen receptor negative, her2/neu negative, progesterone receptor negative, stage ib breast cancer, stage iia breast cancer, stage iib breast cancer, stage iiia breast cancer, stage iiic breast cancer, triple-negative breast carcinoma